Royal Caribbean Cruises Ltd vs Revvity Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $282 (market cap $75.26B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 4.4× Revvity Inc's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (2.13%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Revvity Inc for 12 Days on average.
| RCL | RVTY | |
|---|---|---|
Market Cap | $75.26B | $16.98B |
Volume | 1,958,628 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $157.36 |
52-Week Low | $230.30 | $82.26 |
Typical Hold Time | 85 Days | 12 Days |
Enterprise Value | $97.91B | $19.30B |
Dividend Yield | 2.13% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $282.26, showing minimal daily movement (-0.04%) amid strong fundamental performance. The stock maintains a bullish technical outlook with support at $279 and resistance at $284. Recent earnings beats in Q1 and Q2 2026, coupled with robust revenue growth from $8.8B in 2022 to $17.9B in 2025, highlight operational strength. The company's expansion into resort markets through the $3B Sandals acquisition adds growth diversification while analyst consensus remains positive with a $346.67 price target.
RCL presents a compelling growth story with expanding profit margins and strategic diversification, though elevated debt levels and fuel cost sensitivity pose moderate risks. The stock's current valuation at 17.38x P/E appears reasonable given 45.33% ROE and consistent earnings outperformance. Near-term catalysts include Q3 2026 earnings and continued execution on the Sandals integration, while macroeconomic pressures on travel demand represent the primary headwind.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →